INTERNATIONAL BUSINESS MACHINES CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INTERNATIONAL BUSINESS MACHINES CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.54B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $62.75B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $61.86B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $60.53B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $57.35B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $55.18B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $57.71B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $79.59B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $79.14B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $79.92B | Feb 26, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.30B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $35.55B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $34.30B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $32.69B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $31.49B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $30.87B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $31.53B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $36.94B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $36.94B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $38.52B | Feb 26, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.59B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.02B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.50B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.64B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $5.74B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $5.59B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $9.43B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $8.73B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $5.75B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $11.87B | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.32B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $7.48B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $6.78B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $6.57B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $6.49B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $6.26B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $5.91B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $5.38B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $5.59B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $5.73B | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.12B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $19.69B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $19.00B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $18.61B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $18.75B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $20.56B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $18.72B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $19.37B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $19.68B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $20.87B | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.19B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $13.45B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $13.93B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $10.44B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $12.80B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $18.20B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $14.77B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $15.25B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $16.72B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $17.08B | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.05B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.25B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.35B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $2.06B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $2.62B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $2.29B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $3.40B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $3.23B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $3.57B | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.88B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $137.18B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $135.24B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $127.24B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $132.00B | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $155.97B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $152.19B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $123.38B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $125.36B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $117.47B | Feb 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.14B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $109.78B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $112.63B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $105.22B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $113.01B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $135.24B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $131.20B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $106.45B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $107.63B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $99.08B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.65B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $27.31B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $22.53B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $21.94B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $18.90B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $20.60B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $20.84B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $16.80B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $17.59B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $18.25B | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.72B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $60.71B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $60.18B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $55.95B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $55.64B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $53.77B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $52.47B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $36.27B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $36.79B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $36.20B | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.65B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $151.16B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $151.28B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $149.83B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $154.21B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $162.72B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $162.95B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $159.21B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $153.13B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $152.76B | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.59B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $13.95B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $13.07B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $7.89B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $6.65B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $13.19B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $8.17B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $11.38B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $11.97B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $7.83B | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $42.66B | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $45.05B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $40.89B | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $38.70B | Feb 28, 2017 |
| FY2015 | Dec 31, 2014 | $39.59B | Feb 23, 2016 |
| FY2014 | Dec 31, 2013 | $36.71B | Feb 24, 2015 |
| FY2013 | Dec 31, 2012 | $29.68B | Feb 25, 2014 |
| FY2012 | Dec 31, 2011 | $27.16B | Feb 26, 2013 |
| FY2011 | Dec 31, 2010 | $25.86B | Feb 28, 2012 |
| FY2010 | Dec 31, 2009 | $24.15B | Feb 22, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 6 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 10 | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 9 | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | 6 | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | 12 | Feb 26, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 6 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 10 | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 9 | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | 6 | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | 12 | Feb 26, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 936.95M | Feb 24, 2026 |
| FY2024 | Dec 31, 2024 | 926.29M | Feb 25, 2025 |
| FY2023 | Dec 31, 2023 | 915.01M | Feb 26, 2024 |
| FY2022 | Dec 31, 2022 | 906.09M | Feb 28, 2023 |
| FY2021 | Dec 31, 2021 | 898.07M | Feb 22, 2022 |
| FY2020 | Dec 31, 2020 | 892.65M | Feb 23, 2021 |
| FY2019 | Dec 31, 2019 | 887.11M | Feb 25, 2020 |
| FY2018 | Dec 31, 2018 | 892.48M | Feb 26, 2019 |
| FY2017 | Dec 31, 2017 | 922.18M | Feb 27, 2018 |
| FY2016 | Dec 31, 2016 | 945.87M | Feb 28, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.26B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.15B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $6.04B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.95B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $5.87B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $5.80B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $5.71B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $5.67B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $5.51B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $5.26B | Feb 26, 2019 |